+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics



Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics



Journal of Pharmacokinetics and Pharmacodynamics 34(4): 549-558



Once-daily dosing almost invariably shows a slightly higher percentage of prescribed doses taken than does twice-daily dosing. Many pharmaceutical scientists, regulators, and prescribers have considered this finding to signify the therapeutic superiority of once-daily dosing. The therapeutically more relevant question, however, is not the percentage of prescribed doses taken but the comparative impact of missed doses on the pharmacologic effects of a drug under the two dosing regimens. A key point in this regard is that the pharmacokinetic equivalent of a single missed once-daily dose is 2-3 sequentially omitted twice-daily doses. Thus, an important parameter in comparing the two regimens is the probability of two or three twice-daily doses being sequentially omitted, versus the probability of missing a single once-daily dose. Our data indicate that the probability of sequential omission of 2-3 twice daily doses is half the probability of omission of a single once-daily dose. For that reason, a twice-daily regimen could prove to be superior to a once-daily regimen in maintaining drug concentrations within a therapeutically desirable range. A more important consideration, however, is to maintain not just the concentration of drug in plasma, but the drug's therapeutic action. The duration of therapeutic drug action following a last-taken dose is not only drug-specific, but also, for some drug, dependent on the pharmacodynamic properties. Judging the comparative superiority of one dosing regimen over another requires knowledge of the drug's duration action after a last-taken dose, plus knowledge of the comparative probabilities of the various patterns of dose omission. When applied to HIV protease inhibitors, a twice-daily regimen appears to be better than an once-daily regimen in maintaining therapeutically effective drug actions.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 015733869

Download citation: RISBibTeXText

PMID: 17497202

DOI: 10.1007/s10928-007-9058-0


Related references

Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens. British Journal of Clinical Pharmacology 65(6): 871-878, 2008

Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis. Clinical Therapeutics 2019, 2019

A comparison of four buprenorphine dosing regimens using open-dosing procedures: Is twice-weekly dosing possible?. Addiction 95(7): 1069-1077, 2000

Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer ChemoTherapy and Pharmacology 77(4): 685-692, 2016

Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 30(7): 640-645, 2018

Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrobial Agents and ChemoTherapy 32(12): 1825-1829, 1988

Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. Journal of Antimicrobial ChemoTherapy 69(10): 2797-2803, 2015

Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrobial Agents and ChemoTherapy 55(7): 3476-3484, 2011

The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Methods and Findings in Experimental and Clinical Pharmacology 26(10): 781-788, 2005

Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. Journal of Clinical Pharmacology 54(2): 150-160, 2015

Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology 95(2): 324-333, 2001

Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Therapeutic Drug Monitoring 15(2): 75-82, 1993

Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Journal of Pharmacy and Pharmacology 44(9): 761-765, 1992

Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Journal of Pharmacy and Pharmacology 44(9): 755-760, 1992

Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults. Journal of Clinical Pharmacology 52(1): 18-28, 2012